The Evaluation of Radiation Therapy and Combined-modality Therapy for Non-small-cell Lung Cancer in Elderly

고령의 비소세포성폐암 환자의 방사선 및 병용치료에 대한 효과 평가

  • Yoon, Won-Sup (Hampyeong Community Health Center) ;
  • Yang, Dae-Sik (Department of Radiation Oncology, Korea University College of Medicine) ;
  • Kim, Chul-Yong (Department of Radiation Oncology, Korea University College of Medicine)
  • 윤원섭 (함평군 보건소) ;
  • 양대식 (고려대학교 의과대학 방사선종양학교실) ;
  • 김철용 (고려대학교 의과대학 방사선종양학교실)
  • Published : 2007.06.30

Abstract

[ $\underline{Purpose}$ ]: To compare radiation therapy alone to combined modality therapy about survival rate and tolerance of elderly patients ($70=or{\geq}$) with non-small-cell lung cancer (NSCLC). $\underline{Materials\;and\;Methods}$: Between 1998 and 2002, 57 patients given radiation therapy due to NSCLC (Stage III) were analysed retrospectively. Radiation therapy alone (RT), concurrent chemoradiation (CRT), and sequential chemoradiation (SCRT) was done to 33, 16 and 8 patients, respectively. Patients' median age was 74 (range $70{\sim}85$). Male and female are 51 patients and 6 patients, respectively. 23 patients were stage IIIa and 34 were stage IIIb. Patients' characteristic distribution of RT and CRT was not significantly different except mass size that RT has a bigger than CRT. The fraction size of radiation therapy was 1.8 Gy in CRT and $1.8{\sim}3\;Gy$ in other groups. Total radiation dose was $51{\sim}63\;Gy$ according to the fraction size. If the prescribed total radiation dose was successfully irradiated, we stated that it was completion of radiation therapy. $\underline{Results}$: 52 patients were dead. Median period of radiation therapy was as follow: RT, 35 days, CRT, 60.5 days and SCRT, 35 days. Overall median survival time (MST) was 10.1 months. The 1 yr- and 2 yr-overall survival rate was 39.8% and 17.6%, respectively. MST of RT, CRT and SCRT was 8.9, 8.2 and 11.7 months, respectively. The 1 yr survival rate of RT, CRT and SCRT was 38.4%, 37.5% and 50% (not significant). Patients given incomplete radiation therapy were 12 (RT, 5 CRT, 6 SCRT, 1). N stage (p=0.081) and the difference of treatment methods (p=0.079) were the factors affecting incompletion of radiation therapy, but it was not significant. In case of combined-agents chemotherapy, 4 of 8 ceased radiation therapy. T stage ($T{\geq}3$), mass size (${\geq}5\;cm$), Karnofsky performance scale (${\leq}70$) and completion of radiation therapy were the prognostic factors in uni- and multi-variate analysis. $\underline{Conclusion}$: In elderly patients with NSCLC, radiation therapy alone was a treatment method with similar survival period compared with other methods. Generally, patients given radiation therapy alone was tolerable to a treatment. Before planning concurrent chemoirradiation in elderly patients with NSCLC, physicians pay attention to a selection of patients and chemotherapy agents considering general condition and toxicity.

목 적: 70세 이상 고령의 비소세포성폐암 환자에서 단독방사선치료 및 화학방사선병행요법에 대한 독성과 생존율을 비교하였다. 대상 및 방법: 1998년에서 2002년까지 만 70세 이상의 III기 비소세포성폐암으로 방사선치료를 시행한 57명에 대해 후향적 분석을 시행하였다. 중앙추적조사기간은 9개월($1{\sim}53.4$개월)이었다. 단독방사선치료(갑군)를 시행한 환자가 33명, 동시화학방사선치료(을군)를 시행한 환자가 16명, 화학요법 후 방사선치료(병군)를 시행한 환자가 8명이었다. 남자, 여자가 각각 51, 6명, 중앙연령은 74 ($70{\sim}85$)세였다. IIIa와 IIIb기가 각각 23, 34명이었다. 갑군과 을군의 비교 시 종양의 크기가 갑군이 더 큰 것 외에는 의미 있는 분포의 차이는 없었다. 방사선치료의 분할선량은 동시화학방사선치료 시에는 1.8 Gy로, 그 외의 경우는 방사선치료범위를 고려하여 $1.8{\sim}3\;Gy$로 하였고 분할선량에 따라 $51{\sim}63\;Gy$를 조사하고자 하였다. 계획된 방사선량을 모두 조사받은 경우를 완전종결로 하였고 그렇지 못한 경우를 불완전종결로 하였다. 결 과: 57명 중 52명의 환자가 추적조사기간 중 사망하였다. 갑, 을, 병군에서 완전종결 환자는 28, 10, 7명이었고 중앙방사선치료기간은 각각 35, 60.5, 35일이었다. 전체 환자의 중앙생존기간은 10.1개월이었고 1년, 2년 생존율은 39.8, 17.6%였다. 갑, 을, 병군의 중앙생존기간은 각각 8.9, 8.2, 11.7개월이었고 1년 생존율은 38.4, 37.5, 50%였다. 방사선치료가 불완전 종결된 갑, 을, 병군은 각각 5, 6, 1명으로 N병기(N3)(p=0.081), 치료방법의 차이(p=0.079)가 불완전 종결에 영향을 줄 가능성이 높았다. 을군에서 병용 화학요법제를 시행한 8명 중 4명은 부작용으로 치료를 중단하였다. 예후인자의 평가에서 T병기(T3 이상), 종양의 크기(5 cm 이상), KPS (70 이하), 불완전 종결이 단일변량분석과 다변량분석에서 유의하였다. 결 론: 고령의 비소세포성폐암 환자에서 단독방사선치료는 타 치료와 비교 시 대등한 생존기간을 나타냈으며 동시 화학방사선치료에 비해 부작용으로 치료를 중단하는 경우가 적어 대체로 고령의 환자가 치료에 잘 견디는 치료였다. 고령의 환자에서 동시화학방사선치료를 고려할 시에는 치료의 견딤 정도를 고려하여 환자의 선택 및 약제의 선택에 주의하여야 할 것이다.

Keywords

References

  1. 한국행정연구소. (05/06 전국행정 구역별 상주)인구편람. 1판. 서울; 한국행정연구소, 2005:554-555
  2. Yancik R, Rise LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23 https://doi.org/10.1016/S0889-8588(05)70275-6
  3. Jeremic B, Shibamolo Y, Acimovie L, Djurie L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:452-458 https://doi.org/10.1200/JCO.1995.13.2.452
  4. Jeremie B, Shibamolo Y, Acimovie L, Milisavljevie S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-smallcell lung cancer: a randomized study. J Clin Oncol 1996;14: 1065-1070 https://doi.org/10.1200/JCO.1996.14.4.1065
  5. Dillman RO, Herdon J, Seagren SL, Ealon WL, Green MR. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215 https://doi.org/10.1093/jnci/88.17.1210
  6. Furuse K, Fukuoka M, Kawahara M, el al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699 https://doi.org/10.1200/JCO.1999.17.9.2692
  7. Hirola S, Tsujino K, Endo M, el al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:291-295
  8. Singh AK, Loekell MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:337-341 https://doi.org/10.1016/S0360-3016(02)03937-8
  9. Yamada M, Kudoh S, Hirala K, Nakajima T, Yoshigawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998;3471-75
  10. Furuse K, Kubola K, Kawahara M, el al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995;13:869-875 https://doi.org/10.1200/JCO.1995.13.4.869
  11. Choy H, Akerley W, Safran H, el al. Multiinstitutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16:3316-3322 https://doi.org/10.1200/JCO.1998.16.10.3316
  12. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005:23:3112-3124 https://doi.org/10.1200/JCO.2005.00.141
  13. Firal S, Pleisfer A, Byhardl RW, Gore E. Age ia independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006:29:252-257 https://doi.org/10.1097/01.coc.0000217824.20290.ab
  14. Gauden SJ, Tripeony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001 ;32:71 -79
  15. Jose SS, Arnaiz MD, Lucas A, et al. Radiation therapy alone in elderly with early stage non-small cell lung cancer. Lung Cancer 2006;52:149-154 https://doi.org/10.1016/j.lungcan.2005.12.010
  16. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LA. Radiotherapy alone for medically inoperable stage I nonsmall-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys 1998:40:149-154 https://doi.org/10.1016/S0360-3016(97)00589-0
  17. Cheung PCF, Mackillop WJ, Dixon P, Brundage MD, Youssef YM, Zhou S. Involved-field radiotherapy alone for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000:48703-710
  18. Atagi S, Kawahara M, Tamura T, et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan clinical oncology group (JCOG9812). Jpn J Clin Oncol 2005;35:195-201 https://doi.org/10.1093/jjco/hyi060
  19. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206 https://doi.org/10.1200/JCO.2003.12.019
  20. Lima R, Herndon JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung cancer: an evaluation of two trials of the cancer and leukemia group B. Cancer 2002;94:181-187 https://doi.org/10.1002/cncr.10174
  21. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the cancer and leukemia Group B and the eastern cooperative oncology group. J Clin Oncol 1999;17:4-11 https://doi.org/10.1200/JCO.1999.17.1.4
  22. Lonardi F, Colei M, Pavanato G, Adami F, Gioga G, Camposlrini F. Radiothearpy for non-small cell lung cancer in patients aged 75 and over: safety, effectiveness and possible impact on survival. Lung Cancer 2000;28:43-50 https://doi.org/10.1016/S0169-5002(99)00117-8
  23. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999:45:1143-1149 https://doi.org/10.1016/S0360-3016(99)00325-9
  24. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-364 https://doi.org/10.1378/chest.117.2.358
  25. Pignon T, Gregor A, Koning CS, Roussel A, Van Glabbeke M, Scalliet P. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998:46:239-248 https://doi.org/10.1016/S0167-8140(97)00188-6
  26. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the radiation therapy oncology group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005;63:667-671 https://doi.org/10.1016/j.ijrobp.2005.03.037
  27. Ahn SJ, Chung WK, Nah BS, et al. Outcomes after radiotherapy in inoperable patients with squamous cell lung cancer. J Korean Soc Ther Radiol Oncol 2001 ;19:216-223
  28. Tombolini V, Bonanni A, Donato V, et al. Radiotherapy alone in elderly patients with medically inoperable stage IlIA and IIIB non-small cell lung cancer. Anticancer Res 2000;20:4829-4633